Roche could be just months away from FDA approval of its anti-complement C5 antibody crovalimab, after the US regulator started a review of its marketing application as a treatment for rare disorder ...
Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results